Sorrento Therapeutics to Acquire ACEA for $38M in Stock

BIOTECH: Antibody-Centric Company Grows

■ By NATALLIE ROCHA
EXECUTIVE Q&A

Sorrento Therapeutics (NASDAQ: SRNE) will acquire ACEA Therapeutics in a deal that offers ACEA's equity holders approximately $38 million in common stock, the company announced on April 5. The deal between the two San Diego life science companies is...

Read latest San Diego Business Journal online.

Online newspapers at PressDisplay.